Cutting-Edge Basic Research Awards (CEBRA) (R21 Clinical Trial Optional)

The National Institute on Drug Abuse (NIDA) Cutting-Edge Basic Research Award (CEBRA) is designed to foster highly innovative or conceptually creative research related to the etiology, pathophysiology, prevention, or treatment of substance use disorders (SUDs). It supports high-risk and potentially high-impact research that is sparse or not included in NIDA's current portfolio that has the potential to transform SUD research. The proposed research should: 1) develop and/or adapt revolutionary techniques or methods for addiction research or that show promising future applicability to SUD research; and/or 2) test an innovative and significant hypothesis for which there are scant precedent or preliminary data and which, if confirmed, would transform current thinking. This R21 mechanism supports exploratory and developmental research that may lead to breakthrough discoveries in substance use disorder research.